BeiGene AUS Pty Ltd
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$7.9M
Doctors Paid
3
Transactions
1,698
2024 Total
$3.2M
Payment Breakdown by Category
Research$7.9M (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.9M | 1,698 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies | $3.4M | 0 | 711 |
| A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies | $3.0M | 0 | 808 |
| A Phase I/II, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies | $473,733 | 3 | 26 |
| A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors | $382,415 | 0 | 40 |
| A Phase 1, Open-Label Dose-escalation and Expansion Study to Investigate the Safety Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors | $238,708 | 0 | 17 |
| A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors | $225,673 | 0 | 60 |
| A Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB-3111 with Obinutuzumab in Subjects with B-Cell Lymphoid Malignancies | $133,659 | 0 | 35 |
| A Phase 1b Open Label Dose escalation and Expansion Study to Investigate the Safety Pharmacokineticx and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MIK Inhibitor PD-0325901 in Patients with Advanced or Refractory Solid Tumors | $57,250 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Hematology | $175.00 | 1 | $175.00 |
| Hematology & Oncology | $105.00 | 2 | $52.50 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2020 |
|---|---|---|---|---|
| Jacalyn Rosenblatt, M.d, M.D | Hematology | Boston, MA | $175.00 | $0 |
| David Avigan, M.d, M.D | Hematology & Oncology | Boston, MA | $70.00 | $0 |
| Dr. Eric Jacobsen, Md, MD | Hematology & Oncology | Boston, MA | $35.00 | $0 |
About BeiGene AUS Pty Ltd
BeiGene AUS Pty Ltd has made $7.9M in payments to 3 healthcare providers, recorded across 1,698 transactions in the CMS Open Payments database. In 2024, the company paid $3.2M. The top product by payment volume is BRUKINSA ($522,178).
Payments were distributed across 2 medical specialties. The top specialty by payment amount is Hematology ($175.00 to 1 doctors).
Payment categories include: Research ($7.9M).